Summit X LLC’s Actinium Pharmaceuticals ATNM Stock Holding History

Summit X LLC’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,273	Closed	-$24K	–	448
2020 Q2	$24K	Buy	2,273 +523	+30%	+$3.96K	0.01%	203
2020 Q1	$10K	Buy	1,750 +167	+11%	+$1.19K	﹤0.01%	191
2019 Q4	$10K	Buy	1,583 +416	+36%	+$2.87K	﹤0.01%	234
2019 Q3	$8K	Hold	1,167	–	–	﹤0.01%	228
2019 Q2	$8K	Hold	1,167	–	–	﹤0.01%	234
2019 Q1	$16K	Hold	1,167	–	–	0.01%	238
2018 Q4	$14K	Hold	1,167	–	–	0.01%	201
2018 Q3	$26K	Buy	1,167 +84	+8%	+$1.71K	0.01%	222
2018 Q2	$21K	Buy	+1,083	New	+$13.7K	0.01%	206
2018 Q1	–	Sell	-367	Closed	-$8K	–	185
2017 Q4	$8K	Hold	367	–	–	0.01%	178
2017 Q3	$7K	Hold	367	–	–	﹤0.01%	180
2017 Q2	$13K	Buy	+367	New	+$15.4K	0.01%	179

Other funds holding ATNM

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Summit X LLC's ATNM Position: Q3 2020 in Review

Summit X LLC sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 2,273 shares — an estimated $24K sold.

Summit X LLC first reported a position in ATNM in Q2 2017 and held it in 12 quarters. The position peaked at $26K in Q3 2018. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

Summit X LLC reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Summit X LLC sold 2,273 Actinium Pharmaceuticals shares in Q3 2020, an estimated $24K.
Summit X LLC first reported a position in Actinium Pharmaceuticals in Q2 2017 and held it in 12 quarters.
Summit X LLC's Actinium Pharmaceuticals position peaked at $26K in Q3 2018.
41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on Summit X LLC's 13F filing for Q3 2020, filed 12 Nov 2020.